Status:
COMPLETED
Muscle Lipid and Insulin Resistance in the Elderly
Lead Sponsor:
University of Pittsburgh
Collaborating Sponsors:
National Institute on Aging (NIA)
Conditions:
Obesity
Eligibility:
All Genders
60-75 years
Phase:
NA
Brief Summary
This project will provide novel information concerning the ability of exercise to enhance the capacity for oxidative metabolism of fatty acids and improve insulin resistance in older adults who are at...
Detailed Description
Hypothesis and Specific Aims: 1. To determine whether aerobic exercise improves both skeletal muscle fat distribution and insulin sensitivity of older men and women. We will test two hypotheses. ...
Eligibility Criteria
Inclusion
- 60 - 70 years of age
- No weight gain/loss of \>10 lbs in 6 months
- Sedentary (No more than 1 continuous exercise/week) or Highly trained (\>5 exercise sessions/week for a duration of one year or more)
- Non-Smoker
- BMI 18-38.0
- Resting blood pressure less than 150mmHg systolic/95 mmHg diastolic
- Normal glucose tolerance: Fasting glucose \< 100 mg/dl or 2 hour glucose from OGTT \< 140 mg/dl or impaired glucose tolerance (fasting glucose \> 100 mg/dl \< 126 mg/dl or 2 hour glucose from OGTT \> 140 mg/dl but less than 200 mg/dl
- Note from PCP/Cardiologist for exercise clearance if positive stress test symptoms were observed from GXT
Exclusion
- Clinically significant CVD including h/o MI
- Peripheral Vascular Disease
- Hepatic, renal, muscular/neuromuscular, or active hematologic/oncologic disease
- Clinically diminished pulse
- Presence of bruits in lower extremities
- Previous history of pulmonary emboli
- Peripheral Neuropathy
- Currently not engaged in a regular program and have a V)2 max pre-training value \> 55 ml/kg-fat free mass-min., indicative of moderate fitness OR currently engaged in regular program and having a V)2 max value \< 55 ml/kg-fat free mass-min.
- Anemia (Hematocrit \< 34%)
- Any contraindications to moderate exercise
- Inability and/or willingness to comply with the protocol as written
- Active alcohol or substance abuse (Past 5 years)
- Total cholesterol \> 300 mg/dL
- Triglyceride \> 350 mg/dL
- ALT \> 80, AST \> 80, Alk Phos \> 240
- Proteinuria (defined as \> 1+ on routine dipstick) hypothyroidism (sTSH\>8)
- Therapeutic Doses of Nicotinic Acid
- Type 2 Diabetes: Fasting Glucose \> 126 mg/dl or 2 hour glucose \> 200 mg/dl
- Oral Glucocorticoids
- Females currently on hormone replacement therapy (HRT) less than 6 months
- Claustrophobia
- Previous difficulty with lidocaine or other local anesthetic
- Stress test symptoms:
- Positive ECG (\>2mm ST segment depression) without PCP cardiologist permission to participate
- Signs or symptoms of cardiovascular decomposition (hypotensive response to exercise
- Onset of angina or angina like symptoms, shortness of breath, change in heart rhythm, signs of poor perfusion (light-headedness), tightness
- Hypotension
Key Trial Info
Start Date :
July 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2017
Estimated Enrollment :
92 Patients enrolled
Trial Details
Trial ID
NCT00765505
Start Date
July 1 2004
End Date
December 31 2017
Last Update
February 6 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213